Aspirin in alzheimer's disease: Increased risk of intracerebral hemorrhage: Cause for concern?

Stroke

Volumn 41, Issue 11, 2010, Pages 2690-2692

  Thoonsen, Hanneke ^a   Richard, Edo ^a   Bentham, Peter ^b   Gray, Richard ^c   Van Geloven, Nan ^a   De Haan, Rob J ^a   Van Gool, Willem A ^a   Nederkoorn, Paul J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Department of Psychiatry   (Netherlands)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Alzheimer's disease; aspirin; dementia; ICH; intracerebral hemorrhage

Indexed keywords

ACETYLSALICYLIC ACID;

ALZHEIMER DISEASE; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMPARATIVE STUDY; HAZARD RATIO; HUMAN; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

AGED; ALZHEIMER DISEASE; ASPIRIN; CEREBRAL HEMORRHAGE; HUMANS; INCIDENCE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 78149360575     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.576975     Document Type: Article

References (11)

1. Breteler MMB. Vascular risk factors for Alzheimer's disease: an epide-miologic perspective. Neurobiol Aging. 2003;21:153-160.
2. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197-2204.
3. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MMB. Cerebral white matter lesions and the risk of dementia. Arch Neurol. 2004;61:1531-1534.
4. Rands G, Orrell M, Spector AE. Aspirin for vascular dementia. Cochrane Database Syst Rev. 2000. Issue 4. CD001296. DOI: 10.1002/14651858. CD001296.
5. Bentham P, Gray R, Sellwood E, Hills R, Crome P, Raftery J. Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. Lancet Neurol. 2008;7:41-49.
6. Richard E, Kuiper R, Dijkgraaf MG, Van Gool WA. Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial. J Am Geriatr Soc. 2009;57:797-805.
7. Antitrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373: 1849-1860.
8. Kronmal RA, Hart RG, Manolio TA, Talbert RL, Beauchamp NJ, Newman A. Aspirin use and incident stroke in the Cardiovascular Health Study. Stroke. 1998;29:887-894.
9. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology. 2009;73:674-680
10. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
11. Pettersen JA, Sathiyamoorthy G, Gao FQ, Szilagyi G, Nadkarni NK, St George-Hyslop P, Rogaeva E, Black SA. Microbleed topography, leuko-araiosis, and cognition in probable Alzheimer disease from the Sun-nybrook Dementia Study. Arch Neurol. 2008;65:790-795.